| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC0155 |
| Trial ID | NCT01697527 |
| Disease | Synovial Sarcoma | Melanoma |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| Co-treatment | dendritic cell vaccine therapy|fludeoxyglucose F 18 |
| HLA | HLA-A*02:01 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies |
| Year | 2012 |
| Country | United States |
| Company sponsor | Jonsson Comprehensive Cancer Center |
| Other ID(s) | 12-000153|NCI-2012-01548 |
| Vector information | |||
|
|||
| Cohort1: synovial sarcoma | |||||||||||||||||
|
|||||||||||||||||
| Cohort2: melanoma | |||||||||||||||||
|
|||||||||||||||||